Over the past decade, transcatheter aortic valve replacement (TAVR) has emerged as a less invasive alternative to surgical aortic valve replacement (SAVR) for high-risk surgical candidates and the treatment of choice for inoperable patients with symptomatic, severe aortic stenosis (AS). Recently, there has been explosive growth in the clinical adoption of TAVR worldwide. With this increasing role, intense research efforts have focused on understanding and reducing procedural complications of TAVR, the most common of which are cardiac conduction disturbances.
Two reports in the current issue of EuroIntervention, by Houthuizen et al and Lange et al, focus on cardiac conduction ...
CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR
August 7, 2020